US Broker Ratings

Zoetis Inc. (ZTS) Investor Outlook: A 27.60% Potential Upside in the Animal Health Market

Zoetis Inc. (NYSE: ZTS), a leading player in the animal health industry, continues to capture investor attention with a promising potential upside of 27.60% based on current analyst ratings. With..

Abbott Laboratories (ABT) Stock Analysis: Healthcare Giant Poised for 12.6% Upside

Abbott Laboratories (NYSE: ABT), a titan in the healthcare sector with a market capitalization of $220.16 billion, is capturing the attention of investors with its robust portfolio and promising stock..

Amgen Inc. (AMGN) Stock Analysis: Navigating a 2.25% Potential Upside in the Healthcare Sector

Amgen Inc. (NASDAQ: AMGN), a titan in the healthcare sector, continues to captivate investor interest with its robust portfolio of human therapeutics and a market capitalization of $164.85 billion. With..

Vertex Pharmaceuticals (VRTX) Stock Analysis: Navigating a 7.57% Potential Upside Amid Innovations in Biotechnology

Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX), a prominent player in the biotechnology sector, continues to capture investor attention with its innovative approach to treating cystic fibrosis (CF) and other serious diseases...

Becton, Dickinson and Company (BDX) Stock Analysis: Exploring a 12.43% Upside Potential in the Healthcare Sector

Becton, Dickinson and Company (NYSE: BDX), a stalwart in the medical instruments and supplies industry, presents an intriguing opportunity for investors looking to capitalize on the healthcare sector’s resilience. With..

IQVIA Holdings, Inc. (IQV) Stock Analysis: Navigating Healthcare Innovation with a 6.28% Upside

IQVIA Holdings, Inc. (NYSE: IQV) stands as a formidable player in the healthcare sector, specifically within the diagnostics and research industry. With a staggering market capitalization of $33.86 billion, this..

GSK plc (GSK) Investor Outlook: Exploring a 8.89% Upside Potential

GSK plc (NYSE: GSK), a stalwart in the global healthcare sector, continues to capture investor interest with its robust portfolio and a potential upside of 8.89%. With a market capitalization..

argenx SE (ARGX) Stock Analysis: Exploring a 28.49% Potential Upside with Strong Buy Ratings

argenx SE (ARGX), a commercial-stage biopharmaceutical company headquartered in Amsterdam, Netherlands, is generating significant buzz in the biotechnology sector. With a market capitalization of $36.23 billion, argenx stands as a..

Cencora, Inc. (COR) Stock Analysis: A 13.33% Upside Potential with Robust Growth in Healthcare Distribution

Cencora, Inc. (NYSE: COR), a titan in the medical distribution sector, presents a compelling case for investors seeking exposure to the healthcare industry. With a market capitalization of $56.28 billion,..

Medtronic plc (MDT) Stock Analysis: Evaluating Growth Potential in the Medical Devices Sector

Medtronic plc (NYSE: MDT), a prominent player in the medical devices industry, offers an intriguing investment opportunity for those eyeing the healthcare sector. As a leader in device-based medical therapies,..

Gilead Sciences, Inc. (GILD) Stock Analysis: Insight into Its Investment Potential and Growth Prospects

Gilead Sciences, Inc. (NASDAQ: GILD), a prominent player in the healthcare sector, continues to capture investor interest with its robust pipeline of biopharmaceutical products. As the company stands at a..

Stryker Corporation (SYK) Stock Analysis: Exploring Its Robust Growth and 5.83% Upside Potential

In the ever-evolving landscape of healthcare, Stryker Corporation (NASDAQ: SYK) stands out as a formidable player in the medical devices industry. With a market capitalization of $154.22 billion, Stryker has..

Novo Nordisk (NVO) Stock Analysis: Examining a 19.79% Potential Upside for Investors

Novo Nordisk A/S (NVO), a titan in the healthcare sector, is not just a staple in the field of diabetes and obesity care but also a stock that has captured..

Merck & Company, Inc. (MRK) Stock Analysis: A Healthcare Giant’s 20% Upside Potential

Merck & Company, Inc. (NYSE: MRK), a leading player in the healthcare sector, presents an intriguing opportunity for investors with a potential upside of 20.15%. As a stalwart in the..

Eli Lilly & Company (LLY) Stock Analysis: A $729 Billion Healthcare Giant with 18.36% Potential Upside

Investors looking at the healthcare sector often find themselves drawn to Eli Lilly and Company (NYSE: LLY), a major player in the pharmaceutical industry. With a staggering market capitalization of..

Rapport Therapeutics, Inc. (RAPP) Stock Analysis: Unlocking a 110% Potential Upside in the Biotech Sector

Investors looking to capitalize on the dynamic biotechnology sector may find a compelling opportunity with Rapport Therapeutics, Inc. (NASDAQ: RAPP). This clinical-stage biopharmaceutical company, headquartered in Boston, Massachusetts, is focused..

Abivax SA (ABVX) Investor Outlook: Potential 19% Upside Amid Phase 3 Drug Trials

Abivax SA (ABVX), a Paris-based biotechnology company, is making waves in the healthcare sector with its promising drug candidates targeting chronic inflammatory diseases. With a market capitalization of $4.43 billion..

Cel-Sci Corporation (CVM) Stock Analysis: Unpacking the 3,404% Potential Upside in Biotechnology

Cel-Sci Corporation (NASDAQ: CVM), a clinical-stage biotechnology company headquartered in Vienna, Virginia, has captured investor interest with its ambitious potential upside of 3,404%. This staggering figure is rooted in the..

Humacyte, Inc. (HUMA) Stock Analysis: Exploring a 268% Potential Upside in Biotechnology

Investors with a penchant for biotechnology may find Humacyte, Inc. (NASDAQ: HUMA) an intriguing prospect. The company, headquartered in Durham, North Carolina, is at the forefront of developing off-the-shelf, implantable..

Claritev Corporation (CTEV) Investor Outlook: Navigating Healthcare Data Amidst Volatility

Claritev Corporation (CTEV), a key player in the healthcare sector, is making headlines with its cutting-edge data analytics and technology-enabled solutions aimed at optimizing healthcare cost management and revenue integrity...

US Broker Ratings

US Broker Ratings

FTSE 100

Funds